Table 3 Univariate analysis of variables associated with survival in 170 patients with gastric gastrointestinal stromal tumor (GIST)
From: Prognostic analysis of gastric gastrointestinal stromal tumor with synchronous gastric cancer
Items | Cases (5-year survival rate,%) |  P* |
|---|---|---|
Gender | Â | Â |
Male/Female | 93(77.1)/77(88.2) | Â |
Age (yr) | Â | 0.020* |
≤ 60/>60 | 87(89.3)/83(74.2) |  |
Tumor location | Â | Â |
Upper/Middle/Lower | 75(84.0)/65(76.3)/30(92.1) | Â |
Greatest tumor diameter (cm) | Â | Â |
≤ 2/>2 to 5/>5 to 10/>10 | 54(77.3)/76(92.5)/24(78.4)/16(63.3) |  |
Tumor bleeding | Â | Â |
Yes/No | 16(100.0)/154(80.1) | Â |
Tumor ulceration | Â | Â |
Yes/No | 40(92.3)/130(78.4) | Â |
Mitotic count (/50 HPF) | Â | Â |
≤ 5/>5 to 10/>10 | 135(86.1)/24(67.9)/11(70.7) |  |
Risk stratification | Â | 0.004* |
Very-low | 52(76.2) | Â |
Low | 58(94.2) | Â |
Intermediate | 29(96.6) | Â |
High | 31(58.4) | Â |
CD117 | Â | Â |
(−)/(+) | 33(64.8)/137(85.8) |  |
CD34 | Â | Â |
(−)/(+) | 28(71.2)/142(84.3) |  |
SMA | Â | Â |
(−)/(+) | 112(82.2)/58(82.9) |  |
S-100 | Â | Â |
(−)/(+) | 154(82.3)/16(84.4) |  |
Tumor necrosis | Â | Â |
Yes/No | 8(87.5)/162(81.7) | Â |
Cystic tumor | Â | Â |
Yes/No | 10(100.0)/160(81.6) | Â |
Synchronous gastric cancer | Â | 0.000* |
Yes/No | 42(57.8)/128(90.1) | Â |
SRC in synchronous gastric cancer | Â | Â |
Yes/No | 5(40%)/37(59.2) | Â |
Postoperative complications | Â | Â |
Yes/No | 27(83.8)/141(82.2) | Â |
Postoperative oral imatinib | Â | 0.009* |
Yes/No | 53(97.0)/117(77.3) | Â |